We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Low-Cost and Fast COVID-19 Test Detects SARS-CoV-2 from Pool of Gargle Lavage Samples in One Hour

By LabMedica International staff writers
Posted on 08 Mar 2021
Print article
Image: Researchers Stephan Riesenberg (left) and Lukas Bokelmann (right) in the lab at the St. Georg Hospital Leipzig (Photo courtesy of MPI f. Evolutionary Anthropology)
Image: Researchers Stephan Riesenberg (left) and Lukas Bokelmann (right) in the lab at the St. Georg Hospital Leipzig (Photo courtesy of MPI f. Evolutionary Anthropology)
Researchers have developed a low-cost and fast method to detect COVID-19 infection from a pool of gargle lavage samples.

Researchers of the Max Planck Institute for Evolutionary Anthropology (Leipzig, Germany) have developed improved protocols for the detection of SARS-CoV-2, and the method can detect a positive sample in a pool with 25 uninfected samples in less than one hour. In order to monitor and contain the spread of SARS-CoV-2, it is necessary to test large numbers of people on a regular basis in decentralized settings. Quantitative real-time polymerase chain reaction (qPCR) is the most widely used diagnostic method to detect RNA viruses such as SARS-CoV-2. However, it requires expensive laboratory equipment and global shortages of reagents for RNA purification has increased the need to find simple but reliable alternatives.

One alternative to the qPCR technology is RT-LAMP (reverse transcription loop-mediated isothermal amplification). This test amplifies the desired target sequences of the virus at a constant temperature, using minimal equipment as compared to qPCR. In 2020, RT-LAMP was adapted for the detection of SARS-CoV-2. It was also shown that instead of a swab, which many people find unpleasant, it can be performed on gargle lavage samples.

Max Planck researchers have now developed an improved colorimetric RT-LAMP assay, called Cap-iLAMP (capture and improved loop-mediated isothermal amplification), which extracts and concentrates viral RNA from a pool of gargle lavage samples. After a short incubation, the test result - orange/red for negative, bright yellow for positive - can be interpreted visually or by using a freely available smartphone app. The improved testing method outperforms previous similar methods.

“Cap-iLAMP drastically reduces false positives and single infected samples can be detected in a pool among 25 uninfected samples, thus reducing the technical cost per test to only about 1 Euro per individual”, said senior author Stephan Riesenberg, a researcher at the Max Planck Institute for Evolutionary Anthropology. “Our method overcomes problems associated with standard RT-LAMP and could also be applied to numerous other pathogens.”

Related Links:
Max Planck Institute for Evolutionary Anthropology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.